Apogee Therapeutics announced positive 52-week Phase 2 data for zumilokibart in moderate-to-severe atopic dermatitis, showing durable response with dosing every 3 or 6 months and improved efficacy over time. The company plans to start Phase 3 trials later in 2026 and expand testing into asthma and eosinophilic esophagitis. Apogee also completed a $403 million public offering, boosting its cash position to $1.3 billion, which supports operations through 2029 including a planned Biologics License Application filing for atopic dermatitis. Upcoming milestones include Phase 2 Part B data expected in Q2 2026 and further clinical updates on combination therapies and respiratory indications.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
